CB-839 (telaglenastat)
Renal Cell Carcinoma, NSCLC, AML
Phase 2Discontinued
Key Facts
Indication
Renal Cell Carcinoma, NSCLC, AML
Phase
Phase 2
Status
Discontinued
Company
About Calithera Biosciences
Calithera Biosciences was a U.S.-based public biotech company (NASDAQ: CALA) that developed small-molecule inhibitors targeting key metabolic enzymes like arginase and glutaminase for oncology. It advanced several candidates into clinical trials with the goal of disrupting tumor metabolism and overcoming immunosuppression. Following a strategic review, the company discontinued all development in February 2023, wound down operations, and was dissolved, rendering it a defunct entity with no current valuation or active programs.
View full company profile